Flat dose-response curves for efficacy: what do they mean to the clinician?
Preskorn
Sheldon H
SH
Department of Psychiatry, University of Kansas School of Medicine-Wichita, Wichita, Kansas, USA.
D001291:Attitude of Health Personnel; D003511:Cyclohexanols / Q000008:administration & dosage / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy*; D000069468:Desvenlafaxine Succinate; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005473:Fluoxetine / Q000627:therapeutic use; D006801:Humans; D014179:Neurotransmitter Uptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D017374:Paroxetine / Q000627:therapeutic use; D010820:Physicians; D016032:Randomized Controlled Trials as Topic; D020280:Sertraline / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D003511:Cyclohexanols; D014179:Neurotransmitter Uptake Inhibitors; D005473:Fluoxetine; D017374:Paroxetine; D020280:Sertraline; D000069468:Desvenlafaxine Succinate